Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter seriesPeter A. Nigrović, Gloria C. Higgins, Melissa L. Mannion et al.|Arthritis & Rheumatism|2010Cited by 465
Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national registerFrançois Prince, Lisette W. A. van Suijlekom‐Smit, Marinka Twilt et al.|Annals of the Rheumatic Diseases|2008Cited by 220
Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter studyMarion A. J. van Rossum, T. Fiselier, Marcel J. A. M. Franssen et al.|Arthritis & Rheumatism|1998Cited by 217
Predictors of health‐related quality of life in children and adolescents with juvenile idiopathic arthritis: Results from a web‐based surveyLotte Haverman, Marion A. J. van Rossum, Martha A. Grootenhuis et al.|Arthritis Care & Research|2012Cited by 155
Factors Associated With Treatment Response to Etanercept in Juvenile Idiopathic ArthritisM.H. Otten, Lisette W. A. van Suijlekom‐Smit, Femke H. M. Prince et al.|JAMA|2011Cited by 149